期刊的影响因子--文章列表

期刊文章列表
Kai Yuan^1,2，Xiao Wang^1,2，Haojie Dong^1,2，Wenjian Min^1,2，Haiping Hao^1,2，Peng Yang^1,2（State Key Laboratory of Natural Medicines and Jiangsu Key Laboratory of Drug Design and Optimization，China Pharmaceutical University；Department of Medicinal Chemistry，School of Pharmacy，China Pharmaceutical University）.Selective inhibition of CDK4/6：A safe and effective strategy for developing anticancer drugs[J].Acta Pharmaceutica Sinica B,2021,第1期 Yilan Shen¹，Wei Chen^2,3，Lei Han²，Qi Bian¹，Jiajun Fan²，Zhonglian Cao²，Xin Jin²，Tao Ding¹，Zongshu Xian²，Zhiyong Guo¹，Wei Zhang⁴，Dianwen Ju²，Xiaobin Mei¹（Department of Nephrology，Changhai Hospital，Second Military Medical University；Department of Biological Medicines，Fudan University School of Pharmacy；Department of Ophthalmology，Stanford University School of Medicine；Department of Nephrology，Shanghai Yangpu Hospital of TCM）.VEGF-B antibody and interleukin-22 fusion protein ameliorates diabetic nephropathy through inhibiting lipid accumulation and inflammatory responses[J].Acta Pharmaceutica Sinica B,2021,第1期 Bingchen Zhang¹，Jiali Jiang¹，Pengyu Wu¹，Junjie Zou¹，Jingqing Le¹，Juanfang Lin¹，Chao Li¹，Bangyue Luo¹，Yongjie Zhang¹，Rui Huang²，Jingwei Shao^1,2（Fujian Provincial Key Laboratory of Cancer Metastasis Chemoprevention and Chemotherapy，College of Chemistry，Fuzhou University；Institute of Oceanography，Minjiang University）.A smart dual-drug nanosystem based on coassembly of plant and food-derived natural products for synergistic HCC immunotherapy[J].Acta Pharmaceutica Sinica B,2021,第1期 Jie Cheny，Yan Wangy，Di Zhao，Lingyuan Zhang，Weimin Zhang，Jiawen Fan，Jinting Li，Qimin Zhan（Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing)，Laboratory of Molecular Oncology，Peking University Cancer Hospital & Institute）.Chrysin serves as a novel inhibitor of DGKα/FAK interaction to suppress the malignancy of esophageal squamous cell carcinoma(ESCC)[J].Acta Pharmaceutica Sinica B,2021,第1期 Shun Zhang^1,2,3，Yan Zhao^2,4,5，Shuyuan Wang^2,3，Min Li^2,3，Yue Xu^2,3，Jianhua Ran⁶，Xiaoqiang Geng²，Jinzhao He^2,3，Jia Meng^2,3，Guangying Shao^2,3，Hong Zhou^2,3，Zemei Ge^2,4，Guangping Chen⁷，Runtao Li^2,4，Baoxue Yang^1,2,3（Department of Pharmacology，School of Basic Medical Sciences，Peking University；State Key Laboratory of Natural and Biomimetic Drugs，Peking University；Key Laboratory of Molecular Cardiovascular Sciences，Ministry of Education；School of Pharmaceutical Sciences，Peking University；College of Pharmacy，Inner Mongolia Medical University；Department of Anatomy and Neuroscience Center，Chongqing Medical University；Department of Physiology，Emory University School of Medicine）.Discovery of novel diarylamides as orally active diuretics targeting urea transporters[J].Acta Pharmaceutica Sinica B,2021,第1期 Xiaosa Changy，Dejuan Suny，Danfeng Shiy，Guan Wang，Yanmei Chen，Kai Zhang，Huidan Tan，Jie Liu，Bo Liu，Liang Ouyang（State Key Laboratory of Biotherapy and Cancer Center，West China Hospital，Collaborative Innovation Center of Biotherapy，Sichuan University）.Design, synthesis, and biological evaluation of quinazolin-4（3H）-one derivatives co-targeting poly （ADP-ribose） polymerase-1 and bromodomain containing protein 4 for breast cancer therapy[J].Acta Pharmaceutica Sinica B,2021,第1期 Shuang Zhou¹，Jinbo Li¹，Jiang Yu¹，Liyuan Yang¹，Xiao Kuang¹，Zhenjie Wang¹，Yingli Wang¹，Hongzhuo Liu¹，Guimei Lin²，Zhonggui He¹，Dan Liu³，Yongjun Wang¹（Wuya College of Innovation，Shenyang Pharmaceutical University；School of Pharmaceutical Science，Shandong University；Key Laboratory of Structure-Based Drugs Design & Discovery of Ministry of Education，Shenyang Pharmaceutical University）.A facile and universal method to achieve liposomal remote loading of non-ionizable drugs with outstanding safety profiles and therapeutic effect[J].Acta Pharmaceutica Sinica B,2021,第1期 Bing Zhao¹，Xinhui Zhang¹，Tingting Yu¹，Ying Liu¹，Xiaoling Zhang¹，Yongfang Yao¹，Xuejian Feng¹，Hongmin Liu¹，Dequan Yu²，Liying Ma¹，Shangshang Qin¹（State Key Laboratory of Esophageal Cancer Prevention and Treament，Key Laboratory of Technology of Drug Preparation(Zhengzhou University)，Ministry of Education of China，Key Laboratory of Henan Province for Drug Quality and Evaluation，Institute of Pharmaceutical Research and School of Pharmaceutical Sciences，Zhengzhou University；State Key Laboratory of Bioactive Substance and Function of Natural Medicines，Institute of Materia Medica，Chinese Academy of Medical Sciences and Peking Union Medical College）.Discovery of thiosemicarbazone derivatives as effective New Delhi metallo-β-lactamase-1(NDM-1) inhibitors against NDM-1 producing clinical isolates[J].Acta Pharmaceutica Sinica B,2021,第1期 Jingwei Bian¹，Zijian Li^1,2（Department of Cardiology and Institute of Vascular Medicine，Peking University Third Hospital，Key Laboratory of Cardiovascular Molecular Biology and Regulatory Peptides，Ministry of Health，Key Laboratory of Molecular Cardiovascular Sciences，Ministry of Education，Beijing Key Laboratory of Cardiovascular Receptors Research；Department of Pharmacy，Peking University Third Hospital）.Angiotensin-converting enzyme 2(ACE2)：SARS-CoV-2 receptor and RAS modulator[J].Acta Pharmaceutica Sinica B,2021,第1期 Jinyang Li¹，Jiasheng Lu¹，Haiyan Guo¹，Jianfen Zhou¹，Songli Wang¹，Kuan Jiang¹，Zhilan Chai¹，Shengyu Yao¹，Xiaoyi Wang¹，Linwei Lu²，Cao Xie¹，Yi Chen³，Weiyue Lu^1,4,2,5（Department of Pharmaceutics，School of Pharmacy，Fudan University & Key Laboratory of Smart Drug Delivery(Fudan University)，Ministry of Education and PLA；The Institutes of Integrative Medicine of Fudan University；Chinese Academy of Sciences Shanghai Institute of Materia Medica；State Key Laboratory of Medical Neurobiology and MOE Frontiers Center for Brain Science，Institutes of Brain Science，Fudan University；Minhang Branch，Zhongshan Hospital and Institute of Fudan-Minghang Academic Health System，Minghang Hospital，Fudan University）.A pentapeptide enabled AL3810 liposome-based glioma-targeted therapy with immune opsonic effect attenuated[J].Acta Pharmaceutica Sinica B,2021,第1期 Yu Sun¹，Jiahua Qian²（Department of Traditional Chinese Medicine and Ethnopharmaceuticals，Center for Drug Evaluation，National Medical Products Administration；Center for Drug Evaluation，National Medical Products Administration）.Botanical drug clinical trial：Common issues and future options[J].Acta Pharmaceutica Sinica B,2021,第1期 Zeqi Zhou¹，Xiangbin Wang²，Yankai Fu¹，Xiqing Zhang¹，Changxiao Liu³（Dynamiker Biotechnology Sub-Center，Beijing Key Laboratory for Mechanism Study and Precision Diagnosis of Invasive Fungal Diseases；Beijing Antai Zhiyuan Technology Co.，Ltd.；State Key Laboratory of Drug Delivery Technology and Pharmacokinetics，Tianjin Institute of Pharmaceutical Research）.Letter to the editor：Neutralizing antibodies for the treatment of COVID-19[J].Acta Pharmaceutica Sinica B,2021,第1期 Editoral Office of Acta Pharmaceutica Sinica.Information for Authors[J].药学学报(英文版),2021,第1期首页上一页 9 10 11 尾页共有11页，转到页

期刊文章列表